Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data

Freedland, Stephen J.; Ke, Xuehua; Lafeuille, Marie-Hélène; Romdhani, Hela; Kinkead, Frédéric; Lefèbvre, Patrick; Petrilla, Allison; Pulungan, Zul; Kim, Seung; D’Andrea, Denise; Francis, Peter; Ryan, Charles J.

doi:10.1080/03007995.2021.1879753

Cited by 19 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Male patients aged ≥ 18 years with mCRPC were identified based on PC diagnosis code (ICD-9-CM: 185; ICD-10-CM: C61) during the study period, evidence of surgical/medical castration (defined in the appendix; similar to prior studies [ 25 , 26 ] but with a shorter range for greater inclusivity, ≥ 8 weeks of continued castration therapy was required to define medical castration), and a prescription claim for enzalutamide or abiraterone after castration during the identification period. The index date was defined as the first claim for enzalutamide or abiraterone during the identification period.…”

Section: Methodsmentioning

confidence: 99%

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

George

Ramaswamy

Huang

et al. 2021

Prostate Cancer Prostatic Dis

Self Cite

View full text Add to dashboard Cite

Background Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than white men when treated with certain agents in clinical trials. We analyzed claims data from the Veterans Health Administration (VHA) database to evaluate OS in black and white men treated with enzalutamide or abiraterone (novel hormonal therapy [NHT]) for chemotherapy-naïve mCRPC. Methods Patients with mCRPC aged ≥18 years were identified in the VHA database by diagnosis codes, evidence of surgical/medical castration, and a prescription claim for enzalutamide or abiraterone after castration from April 2014–March 2017. Cox models assessed associations between race and OS. Unadjusted and multivariable analyses were performed on the entire population and subsets based on the type of therapy received (if any) after NHT. Results In total, 2910 patients were identified (787 black, mean 71.7 years; 2123 white, mean 74.0 years). Median follow-up was 19.0 and 18.7 months in blacks and whites, respectively. Black men had better survival versus white men: hazard ratios (95% CIs) were 0.89 (0.790–0.996; P = 0.044) and 0.67 (0.592–0.758; P < 0.0001) in the unadjusted and multivariable models, respectively. Statistically significantly longer OS was seen in black versus white men regardless of subsequent treatment, including no subsequent treatment. Conclusions In the VHA, black men with chemotherapy-naïve mCRPC initiating NHT may have better outcomes than similarly treated white men.

show abstract

Section: Methodsmentioning

confidence: 99%

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

George

Ramaswamy

Huang

et al. 2021

Prostate Cancer Prostatic Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…We hope the algorithms by Freedland et al 1 will meet the opportunity to get further validation in order to better evaluate and confirm their performance. Moreover, it would be worthwhile if further applications of the algorithms could take place in countries where there are far fewer insurance coverage issues of population, such as in European countries, so that the enrolled population may be more representative.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…We read the interesting work of Freedland et al focusing on a more effective identification of patients with metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castrationresistant prostate cancer (mCRPC) based on health claims and laboratory data 1 . By facilitating the appropriate identification of mCSPC and mCRPC, this study achieved the objective to fill a gap in the literature, as well as to support a better understanding of patient characteristics and unmet needs in real-world settings.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Administrative health claims and laboratory data to identified mCRPC or mCSPC patients: the way to go looks long but promising

Frantellizzi

Pontico

Vincentis

2021

Current Medical Research and Opinion

View full text Add to dashboard Cite

“…Yet, there is limited long‐term population‐based data for men diagnosed with prostate cancer 4,5 . Most population‐based registry studies have reported on up to 5 years of follow‐up 7–10 . However, the 10‐year relative survival rate for prostate cancer is 98% 11 .…”

Section: Introductionmentioning

confidence: 99%

Using health insurance claims data to assess long‐term disease progression in a prostate cancer cohort

et al. 2022

View full text Add to dashboard Cite

Background: Long-term population-based cohort studies of men diagnosed with prostate cancer are limited. However, adverse outcomes can occur many years after treatment. Herein, we aim to assess the utility of using claims data to identify prostate cancer progression 10−15 years after diagnosis. Methods:The study population was derived from the North Carolina−Louisiana Prostate Cancer Project (PCaP). PCaP-North Carolina (NC) included 1031 men diagnosed with prostate cancer from 2004 to 2009. An initial follow-up with a survey and manual medical record abstraction occurred from 2008 to 2011 (Followup 1). Herein, we extended this follow-up with linkage to healthcare claims data from North Carolina (2011−2017) and a second, supplementary 10-year follow-up survey (2018−2020) (Follow-up 2). Vital statistics data also were utilized. Long-term oncological progression was determined using these data sources in combination with expert clinical input.Results: Among the 1031 baseline PCaP-NC participants, 652 were linked to medical claims. Forty-two percent of the men had insurance coverage for the entire 72 months of follow-up. In addition, 275 baseline participants completed the supplementary 10-year follow-up survey. Using all sources of follow-up data, we identified a progression event in 259 of 1031 (25%) men with more than 10 years of follow-up data after diagnosis.

show abstract

Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data

Cited by 19 publications

References 29 publications

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Administrative health claims and laboratory data to identified mCRPC or mCSPC patients: the way to go looks long but promising

Using health insurance claims data to assess long‐term disease progression in a prostate cancer cohort

Contact Info

Product

Resources

About